723 studies found for:    7e11
Show Display Options
Rank Status Study
1 Unknown  Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: 177Lu-CYT-500
2 Completed ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty
Conditions: Spinal Anesthesia;   Total Knee Replacement Arthroplasty
Interventions: Drug: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 11 mg with epinephrine 100 mcg;   Drug: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
3 Unknown  Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging
Condition: Skin Aging
Interventions: Other: Omega7 Sea Buckthorn Oil Cream;   Other: Base cream;   Dietary Supplement: SBA24 Sea Buckthorn Oil Capsule
4 Completed
Has Results
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: MART-1: 26-35(27L) Peptide;   Drug: Montanide ISA 51 VG;   Drug: gp100:154-162 Peptide;   Procedure: Radiation;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Genetic: Anti-gp 100:154 TCR PBL;   Genetic: Anti-MART-1 F5 TCR PBL
5 Completed
Has Results
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
Conditions: Active Rheumatoid Arthritis;   Arthritis, Rheumatoid;   Rheumatoid Arthritis
Intervention: Drug: etanercept
6 Completed
Has Results
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo;   Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;   Drug: Diphenhydramine
7 Terminated A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
Condition: Cystitis, Interstitial
Interventions: Biological: Tanezumab;   Other: Placebo
8 Recruiting Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
Condition: Axial Spondyloarthritis
Interventions: Biological: adalimumab;   Biological: Placebo
9 Recruiting Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Condition: Rheumatoid Arthritis
Interventions: Biological: Secukinumab (AIN457);   Biological: Placebo
10 Completed Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Drug: chlorambucil;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: fludarabine phosphate;   Drug: prednisolone;   Drug: vincristine sulfate
11 Completed
Has Results
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab SC;   Drug: tocilizumab IV;   Drug: placebo to tocilizumab SC;   Drug: placebo to tocilizumab IV;   Drug: Disease-modifying antirheumatic drugs (DMARDs)
12 Active, not recruiting A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
13 Recruiting A Study in Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: Adalimumab;   Drug: Baricitinib
14 Enrolling by invitation Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
15 Recruiting Secukinumab in TNF-IR Psoriasis Patients.
Condition: Psoriasis
Interventions: Biological: Secukinumab 150 mg;   Biological: Secukinumab 300 mg
16 Enrolling by invitation Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients
Condition: Rheumatoid Arthritis
Intervention: Drug: SAR153191 (REGN88)
17 Recruiting Window of Opportunity Trial of ADXS 11-001 Vaccination Prior to Robotic Surgery of HPV-Positive Oropharyngeal Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Intervention: Biological: ADXS11-001 (ADXS-HPV)
18 Terminated An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: ADXS11-001 (Lm-LLO-E7);   Drug: Placebo Control
19 Recruiting Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: CP-690,550
20 Recruiting A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Condition: Psoriasis
Intervention: Drug: CP-690,550

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years